You may be eligible for an exciting program to treat those frown lines! Come in During July 2015, and enjoy $75 off your first treatment of Dysport. If you’re loving your results, come back and enjoy up to $195 of additional savings on your next 3 treatments.* That’s a total of $270 in discounts!
To take advantage of these valuable treatment certificates and rewards, you need to enroll in the new ASPIRE Galderma Rewards program. It’s free, and membership gives you instant access to discounts and other rewards. You’ll receive a $20 Galderma treatment certificate just for signing up (this certificate cannot be applied to your first Dysport treatment). If you’d like to join now, visit ASPIRErewards.com, or we can help.
Call us and set up an appointment today.
Limited supplies. Offer valid while supplies last. Can not be combined with any other offer or discount. Please check at time of your appointment for eligibility and availability.
*Offer terms and conditions apply. For details, see below.
Dysport Seeing is Believing Offer Terms & Conditions
This offer is limited to adult patients who receive Dysport treatment for the temporary improvement of the look of moderate to severe frown lines between the eyebrows (glabellar lines). This offer provides a $75 discount for the first treatment of Dysport and a separate $75 discount for the second treatment of Dysport. To participate in this offer, you must enroll in the ASPIRE Galderma Rewards program and receive a Dysport treatment from a participating healthcare provider between May 1 and June 30, 2015. Your second Dysport treatment must occur at least three months after your first treatment and between August 1 and November 30, 2015. This is a limited quantity offer subject to availability from your participating healthcare provider. If you have questions about this offer, please call 1-844-5ASPIRE.
First Dysport Treatment. To receive your first $75 discount: (1) you must enroll in the ASPIRE Galderma Rewards program, (2) you must receive your first Dysport treatment between May 1 and June 30, 2015, and (3) your treatment provider must submit a valid Dysport treatment certificate coupon code to the ASPIRE Galderma Rewards program on your behalf at the time of your treatment. A second treatment is not required to participate in this offer or receive your first $75 discount.
Second Dysport Treatment. By August 1, 2015, you will receive through your ASPIRE Galderma Rewards membership account a Galderma treatment certificate coupon code for your second Dysport treatment. To receive your second $75 discount: (1) you must receive your second Dysport treatment between August 1 and November 30, 2015, but your second treatment must occur at least 3 months after your first Dysport treatment, and (2) your treatment provider must submit your valid Dysport treatment certificate coupon code to the ASPIRE Galderma Rewards program on your behalf at the time of your treatment.
ASPIRE Galderma Rewards. Enrollment in the ASPIRE Galderma Rewards program is required. Upon enrollment in the program, you will receive a $20 Galderma treatment certificate redeemable for any future Galderma aesthetic treatment, excluding your first Dysport treatment under this offer. You will also earn 200 ASPIRE points for each Dysport treatment you purchase. If you purchase four Dysport treatments in a two year period, you will receive 200 additional ASPIRE points, for a total of 1,000 points valued at $100 (200 ASPIRE points = $20). ASPIRE points may be redeemed in the Rewards Boutique at www.ASPIRErewards.com. All points and participation in ASPIRE Galderma Rewards are subject to the ASPIRE Galderma Rewards Consumer Loyalty Program Terms and Conditions.
You are eligible for this offer only if you paid for your entire treatment yourself and if no part of your treatment was covered by insurance or any other third party payor. This offer excludes any treatment using a Galderma product that is reimbursed by Medicaid, Medicare, or any other federal or state benefit programs, including state medical assistance programs. You are not eligible for this offer if your private insurance, HMO, or any other health benefit program paid for all or part of your treatment. If any form of reimbursement is sought from a third-party, you may be required to disclose the value of the coupon(s) to that party. This offer is available only to patients, excluding claims from Galderma employees and their spouses.
This offer is non-transferrable and available and valid only from participating healthcare providers. All Dysport treatment certificate coupon codes must be submitted by the treating provider via www.ASPIREhcp.com. Galderma will reimburse the healthcare provider for the face value of the coupon provided that the provider and consumer have complied with these terms and conditions. Individual treatment certificate coupon codes are valid for one-time use. This offer is limited to two treatment certificate coupon codes per patient and cannot be combined with any other offer or promotion except the ASPIRE Galderma Rewards program. Limit one treatment certificate coupon code per patient per treatment. Treatment certificate coupon codes have no cash value without simultaneous purchase of Dysport treatment, and are void if sold, transferred or exchanged. Offer valid only in the U.S., excluding territories, and void where prohibited, taxed or otherwise restricted by law.
By participating in this offer, you agree to all of the terms and conditions of this offer. Galderma reserves the right to cancel or modify this offer without notice. Galderma assumes no responsibility for lost, late, incomplete, or incorrect submissions that fail to be properly entered and submitted to www.ASPIREhcp.com for any reason. Treatment certificate coupon codes will be processed and reimbursed in U.S. dollars only.
Dysport is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age.
IMPORTANT SAFETY INFORMATION
Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.
Dysport is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.
This product may contain trace amounts of cow’s milk protein. Patients known to be allergic to cow’s milk protein should not be treated with Dysport.
Dysport is contraindicated for use in patients with infection at the proposed injection site(s).
DOSAGE AND ADMINISTRATION
The potency Units of Dysport are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.
WARNINGS AND PRECAUTIONS
Facial Anatomy in the Treatment of Glabellar Lines
Caution should be exercised when administering Dysport to patients with surgical alterations to the facial anatomy, excessive weakness or atrophy in the target muscle(s), marked facial asymmetry, inflammation at the injection site(s), ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin or the inability to substantially lessen glabellar lines by physically spreading them apart.
Do not exceed the recommended dosage and frequency of administration of Dysport. In clinical trials, subjects who received a higher dose of Dysport had an increased incidence of eyelid ptosis.
Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin.
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of Dysport.
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote. No cases of transmission of viral diseases or CJD have ever been reported for albumin.
Intradermal Immune Reaction
The possibility of an immune reaction when injected intradermally is unknown.
The safety of Dysport for the treatment of hyperhidrosis has not been established.
In clinical studies, the most frequently reported adverse events (>2%) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis and nausea.
Patients treated concomitantly with botulinum toxins and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should be observed closely because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of Dysport may potentiate systemic anticholinergic effects such as blurred vision.
The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of Dysport.
USE IN SPECIFIC POPULATIONS
Dysport is not recommended for use in children or pregnant women.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Dysport Full Prescribing Information including Medication Guide.